SAVOR: La baisse de la glycémie dans le haut risque cardiovasculaire, pas d'effet clinique et peut-être un risqueCardiologie cardinale. 2013, Vol 7, Num 56, issn 1960-1646, p. 69Conference Paper

Saxagliptin: A Review of its Use as Combination Therapy in the Management of Type 2 Diabetes Mellitus in the EUYANG, Lily P. H.Drugs (Basel). 2012, Vol 72, Num 2, pp 229-248, issn 0012-6667, 20 p.Article

Efficacy of saxagliptin as an add-on to oral monotherapy in the phase 3 clinical development program: Predictive factors of the treatment response in type 2 diabetesGAUTIER, J.-F; SAUVANET, J.-P.Annales d'endocrinologie. 2011, Vol 72, Num 4, pp 287-295, issn 0003-4266, 9 p.Article

Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trialGÖKE, B; GALLWITZ, B; ERIKSSON, J et al.International journal of clinical practice (Esher). 2010, Vol 64, Num 12, pp 1619-1631, issn 1368-5031, 13 p.Article

Carbon-14 labeling of Saxagliptin (BMS-477118)KAI CAO; BONACORSI, Samuel J; BALASUBRAMANIAN, Balu et al.Journal of labelled compounds & radiopharmaceuticals. 2007, Vol 50, Num 13-14, pp 1224-1229, issn 0362-4803, 6 p.Article

Gliptines: troubles graves pancréatiques, cutanésLa Revue Prescrire. 2014, Vol 34, Num 363, issn 0247-7750, p. 22Article

Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trialsGRUNBERGER, George.European journal of clinical pharmacology. 2014, Vol 70, Num 11, pp 1277-1289, issn 0031-6970, 13 p.Article

Quel médicament utiliser après la métformine pour traiter le diabète de type 2? = What Comes After Metformin for Type 2 Diabetes?The Medical letter on drugs and therapeutics (Edition française). 2012, Vol 34, Num 17, pp 69-70, issn 0253-8512, 2 p.Article

Saxagliptine (ONGLYZA°) en ajout à une insuline: Stop aux gliptines ! = Saxagliptin with insulin : stop gliptines !La Revue Prescrire. 2012, Vol 32, Num 349, issn 0247-7750, p. 811Article

An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical developmentVIERECK, Christopher; BOUDES, Pol.Contemporary clinical trials. 2011, Vol 32, Num 3, pp 324-332, issn 1551-7144, 9 p.Article

Pharmacology of Dipeptidyl Peptidase-4 Inhibitors: Similarities and DifferencesBAETTA, Roberta; CORSINI, Alberto.Drugs (Basel). 2011, Vol 71, Num 11, pp 1441-1467, issn 0012-6667, 27 p.Article

Saxagliptine ^(ONGLYZA°): Aussi peu efficace que les autres gliptines et un potentiel élevé d'interactions médicamenteuses = Saxagliptine : a critical study about efficacy and drug interactionsLa Revue Prescrire. 2010, Vol 30, Num 323, pp 646-651, issn 0247-7750, 6 p.Article

Saxagliptin Added to a Thiazolidinedione Improves Glycemic Control in Patients with Type 2 Diabetes and Inadequate Control on Thiazolidinedione AloneHOLLANDER, Priscilla; JIA LI; ALLEN, Elsie et al.The Journal of clinical endocrinology and metabolism. 2009, Vol 94, Num 12, pp 4810-4819, issn 0021-972X, 10 p.Article

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safetyDEACON, Carolyn F; HOLST, Jens J.Expert opinion on pharmacotherapy. 2013, Vol 14, Num 15, pp 2047-2058, issn 1465-6566, 12 p.Article

Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Combination with MetforminFASS, Andrea D; GERSHMAN, Jennifer A.Advances in therapy. 2013, Vol 30, Num 4, pp 337-353, issn 0741-238X, 17 p.Article

Predictors of medication adherence in patients with type 2 diabetes mellitusCURKENDALL, Suellen M; THOMAS, Nina; BELL, Kelly F et al.Current medical research and opinion. 2013, Vol 29, Num 10, pp 1275-1286, issn 0300-7995, 12 p.Article

Saxagliptine + metformine (KOMBOGLYZE°): Surtout des inconvénients = Saxagliptin + metformin : mainly disadvantagesLa Revue Prescrire. 2012, Vol 32, Num 349, issn 0247-7750, p. 811Article

Dipeptidyl Peptidase-4 Inhibition: Linking Chemical Properties to Clinical SafetyMATTEUCCI, E; GIAMPIETRO, O.Current medicinal chemistry. 2011, Vol 18, Num 31, pp 4753-4760, issn 0929-8673, 8 p.Article

The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus-Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 StudySCIRICA, Benjamin M; BHATT, Deepak L; RAZ, Itamar et al.The American heart journal. 2011, Vol 162, Num 5, pp 818-825, issn 0002-8703, 8 p.Article

Tolerability of Dipeptidyl Peptidase-4 Inhibitors: A ReviewRICHARD, Kathleen R; SHELBURNE, Jamie S; KIRK, Julienne K et al.Clinical therapeutics. 2011, Vol 33, Num 11, pp 1609-1629, issn 0149-2918, 21 p.Article

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type ₂ diabetes mellitusSCHEEN, André J; CHARPENTIER, Guillaume; JOHAN ÖSTGREN, Carl et al.Diabetes/metabolism research and reviews (Print). 2010, Vol 26, Num 7, pp 540-549, issn 1520-7552, 10 p.Article

Saxagliptin: A New Dipeptidyl Peptidase 4 Inhibitor for Type 2 DiabetesBORJA-HART, Nancy L; WHALEN, Karen L.The Annals of pharmacotherapy. 2010, Vol 44, Num 6, pp 1046-1053, issn 1060-0280, 8 p.Article

Saxagliptin: New Therapy for Type 2 DiabetesLOGAN, Jill K; ESCANO, Alisa K.The Journal of pharmacy technology. 2010, Vol 26, Num 3, pp 123-128, issn 8755-1225, 6 p.Article

saxagliptine ^(ONGLYZA°) seule ou associée: Pas moins de complications, peut-être plus d'insuffisances cardiaquesLa Revue Prescrire. 2014, Vol 34, Num 366, issn 0247-7750, p. 256Article

Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with Type 2 diabetesROSENSTOCK, J; GROSS, J. L; AGUILAR-SALINAS, C et al.Diabetic medicine. 2013, Vol 30, Num 12, pp 1472-1476, issn 0742-3071, 5 p.Article